By Fineline Cube 
Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious, patient‑enriched trial testing its once‑daily oral small‑molecule GLP‑1 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi‑center trial will recruit 1,205 patients with Fontaine Stage II disease and is slated for completion in June 2028.
What Orforglipron Brings to the PAD Landscape
Orforglipron is a non‑peptide, orally disintegrating small‑molecule GLP‑1 RA that offers remarkable dosing flexibility—patients can take it any time of day, regardless of meals or fluids. The compound was first identified by Chugai Pharmaceutical Co., Ltd., before Lilly secured a development license in 2018.
Previous phase 3 studies (ACHIEVE‑1 & ACHIEVE‑3) already delivered topline success, showing superior reductions in glycated hemoglobin (A1C), beta‑cell preservation, and weight loss compared to the benchmark GLP‑1 RA, semaglutide (7 mg and 14 mg).
ATTAIN‑PAD: A Milestone for Cardiovascular Therapeutics
The ATTAIN‑PAD study will test orforglipron’s efficacy in improving limb perfusion and walking distance in the largest PAD cohort to date. With 1,205 participants across North and South American sites, the trial will provide robust data on cardiovascular safety and potential morbidity benefits.
Investment Outlook
Eli Lilly’s entry into the PAD arena underscores the broader shift toward oral GLP‑1 therapies for cardio‑metabolic conditions. Investors will be watching the 2028 completion dates for any pivotal data that could broaden orforglipron’s indication portfolio and compete with existing GLP‑1 RA offerings.-Fineline Info & Tech